Hostname: page-component-586b7cd67f-vdxz6 Total loading time: 0 Render date: 2024-11-20T13:25:33.148Z Has data issue: false hasContentIssue false
  • English
  • Français

P03-370 - Effect of Transcranial Magnetic Stimulation in Pharmacoresistant Depression

Published online by Cambridge University Press:  17 April 2020

P. Sakkas ,
E. Tzavellas ,
R. Zaloni ,
T. Paparrigopoulos  and
G. Papadimitriou
P. Sakkas
Affiliation:
Psychiatry, University of Athens School of Medicine, Athens, Greece
E. Tzavellas
Affiliation:
Psychiatry, University of Athens School of Medicine, Athens, Greece
R. Zaloni
Affiliation:
Psychiatry, University of Athens School of Medicine, Athens, Greece
T. Paparrigopoulos
Affiliation:
Psychiatry, University of Athens School of Medicine, Athens, Greece
G. Papadimitriou
Affiliation:
Psychiatry, University of Athens School of Medicine, Athens, Greece

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background

Transcranial magnetic stimulation (TMS) is a novel treatment for patients with depressive disorder. TMS is a noninvasive method to excite neurons in the brain: weak electric currents are induced in the tissue by rapidly changing magnetic fields. We report two cases suffering from pharmacoresistant depression and the efficacy of TMS in their treatment.

Cases

The first case was a 45-year-old male Caucasian patient suffering from unipolar depression and the second case was a 53-year-old female Caucasian patient suffering from bipolar depression.

The patients were under treatment with SSRI, SNRI, NASSA (one medicine or combination of them) without any or minor improvement.

So TMS sessions were performed daily in both patients for a period of one month.

Discussion

A marked reduction of depressive symptoms was demonstrated in both patients. Thus, TMS sessions may help the pharmacoresistant depression by minimizing physical and subjective discomfort. Furthermore TMS appears to be safer and better tolerated than many others medicines or electroconvulsive therapy. Further studies are needed in order to investigate the effect of TMS in resistant depression

Type
Psychopharmacological treatment and biological therapies
Information
European Psychiatry , Volume 25 , Issue S1: 18th European Congress of Psychiatry. February 27, March 2, 2010 - Munich, Germany , 2010 , 25-E976
Copyright
Copyright © European Psychiatric Association 2010
Submit a response

Comments

No Comments have been published for this article.